Eli Lilly (NYSE: LLY) has offloaded three non-alcoholic steatohepatitis (NASH) programs to Sino-American biotech startup Terns Pharmaceuticals, which will take on global development and commercialization of the small molecule candidates.
The agreement covers TERN-101, a clinical stage farnesoid X receptor (FXR) agonist, and TERN-201, a semicarbazide-sensitive amine oxidase (SSAO) inhibitor the firm says is nearing Investigational New Drug (IND) submission, plus a preclinical candidate.
Terns, which was founded a year ago via a $30 million series A funding round from Lilly Asia Ventures, says it will focus initial development activities on regulatory approval in China and explore clinical development in additional global markets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze